
The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

A supplemental new drug application has been submitted to the FDA for the use of regorafenib (Stivarga) as a second-line treatment for patients with unresectable hepatocellular carcinoma.

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Patients with symptoms of cognitive impairment who practiced web-based memory and mental processing exercises over a period of 15 weeks experienced marked improvement in their cognitive function.

A subgroup analysis from a phase III, open-label, randomized study showed that eribulin had comparable activity to dacarbazine in patients with leiomyosarcoma.

Sundar Jagannath, MD, discusses the importance of the standardization of a 3-drug regimen for newly diagnosed multiple myeloma, how the regimen may evolve going forward, and other novel agents on the horizon.

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Palbociclib demonstrated consistent improvement in progression-free survival when combined with endocrine therapy in patients with advanced estrogen receptor-positive breast cancer.

When envisioning the future treatment paradigms for myelodysplastic syndromes and acute myeloid leukemia, researchers predict that hypomethylating agents, immunotherapies, and multikinase and BCL-2 inhibitors are just a few examples of what the field can expect in the coming years.

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Results from the phase II CheckMate-275 trial demonstrated favorable safety and efficacy with the PD-1 inhibitor nivolumab as a second-line treatment for patients with metastatic urothelial cancer who have progressed on first-line chemotherapy.

Both myelofibrosis and polycythemia vera are myeloproliferative neoplasms with very specific characteristics and treatment strategies.

Surgery and radiation therapy are standard treatment options for localized prostate cancer, but are not comparative to one another.

The FDA granted a priority review to ribociclib for use in combination with letrozole as a frontline therapy for patients with hormone-receptor–positive, HER2-negative advanced breast cancer.

While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.

A new clinical trial for women with clinically aggressive triple-negative breast cancer (TNBC) will test a novel theory: Will a diet low in an essential nutrient make TNBC cells more vulnerable to cell killing by a new cancer drug?

Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others.

The European Medicines Agency has accepted and validated a marketing authorization application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

The FDA has has granted a priority review to a new drug application for brigatinib for patients with metastatic ALK-positive non–small cell lung cancer who are resistant to prior crizotinib.


CVS Health has changed its mind about excluding physician-owned dispensaries from Medicare Part D drug distribution.

Novel agents being explored in the landscape of both peripheral and cutaneous T-cell lymphomas could lead to an expansion of treatment options for patients.

Before undergoing surgery, radiation therapy, or a systemic treatment, Clayton S. Lau, MD, advises that the active surveillance approach for some patients with early prostate cancer is likely a more effective approach—but they should be better educated on it.

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

As more agents are approved in the treatment paradigm of chronic lymphocytic leukemia, researchers are exploring frontline options—in addition to ibrutinib and the regimen of fludarabine, cyclophosphamide, and rituximab—in ongoing trials.

Several recent trials have supported the use of chemotherapy in the frontline setting for patients with hormone-sensitive metastatic prostate cancer.

Single-agent olaparib significantly improved progression-free survival compared with placebo in the maintenance setting for patients with advanced BRCA-positive ovarian cancer.